Sj. Czuczwar et al., INFLUENCE OF COMBINED TREATMENT WITH NMDA AND NON-NMDA RECEPTOR ANTAGONISTS ON ELECTROCONVULSIONS IN MICE, European journal of pharmacology, 281(3), 1995, pp. 327-333
-3-hydroxy-5-methyl-isoxazole-4-propionate/kainate (AMPA/kainate) rece
ptor antagonists (at subthreshold doses against electroconvulsions), -
4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466 at maxim
ally 5 mg/kg) and 3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (
NBQX at maximally 20 mg/kg) enhanced the protective effects of NMDA re
ceptor antagonists, MK-801 (dizocilpine) or (2-carboxypiperazine-4-yl)
-1-propenyl-1-phosphonic acid (D-CPP-ene), against electroconvulsions.
Similarly, MK-801 or D-CPP-ene reduced the ED,, values of both NBQX a
nd GYKI 52466 against maximal electroshock. The adverse effects of D-C
PP-ene, evaluated in the chimney and rotorod tests, were potentiated b
y both GYKI 52466 (2.5 mg/kg) and NBQX (10 mg/kg). Also, D-CPP-ene (0.
1 mg/kg) worsened the motor performance of mice pretreated with GYKI 5
2466 in the rotorod test. Neither MK-801 (0.025 mg/kg) nor D-CPP-ene (
0.1 mg/kg) affected the NBQX-induced impairment of motor coordination.
Similarly, GYKI 52466 (2.5 mg/kg) or NBQX (10 mg/kg) did not influenc
e the performance of mice treated with MK-801 (0.2 mg/kg). It may be c
oncluded that the blockade of more than one subtype of glutamate recep
tors leads to a more pronounced anticonvulsive effect when compared wi
th the effect of blockade of an individual receptor subtype. In some c
ases more efficient seizure protection was not associated with increas
ed adverse effects.